- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
HEMO
LSE
Week ended 07 Aug 2026
Weekly Investor Report
Hemogenyx Pharmaceuticals Plc · Healthcare · Biotechnology
Latest close
6.35 GBP
3.3%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -98.9% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned 3.3%, after a -18.1% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 51/100.
Setup score
20
out of 100
Latest Close
6.35 GBP
7 Aug 2026
1W Return
3.3%
latest completed week
4W Return
-18.1%
short-term follow-through
12W Return
-99.1%
quarterly tape
Trend Breadth
48.1%
25 of 52 weeks active
Volume Ratio
1.0x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
3.3%
Latest completed week; four-week move -18.1%.
Indicator stack
26/28
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 36.85%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
News sentiment
51/100
14 relevant articles in the latest sentiment read.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -98.9% below the Trend Line and sits at 0.0% of its 52-week range. The latest completed week returned 3.3%, after a -18.1% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 1.0x the 13-week average. Participation is around or above normal and provides reasonable confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0712-week average 0.21
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.07Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -18.1% over four weeks, -99.1% over 12 weeks, and -95.7% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year25
Trend breadth48.1%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.33Latest activity-pressure read.
Pressure change18.7%Four-week change in activity pressure.
Leadership-99.12Latest relative-leadership reading.
RS change-0.2%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Dec 2025
Field coverage 55%
Model confidence 43%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength57/100Blend of value, momentum, and quality. Underlying universe rank 44; rank 1 is best.
Value53/100Relative valuation strength. Underlying universe rank 48; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum54/100Medium-term price momentum. Underlying universe rank 47; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -383.3% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- -216.7% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- -0.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity-
No recent insider transactions are stored for this company.
News sentiment51/100
Weighted news tone is neutral across 14 relevant articles.
1 positive · 13 neutral · 0 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-99.6%Distance below the 52-week high.
13-week volatility27.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher12 of 2614 weeks finished lower.
Best week+14.3%Week of 12 Jun.
Worst week-99.0%Week of 5 Jun.
Latest week+3.3%Week of 7 Aug.
Shape of recent returns
Strong gains5
Modest gains7
Flat weeks0
Modest losses4
Sharp losses10
Recent vol27.0%13-week weekly-return volatility.
Base vol35.5%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew19.8% / -13.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorGB Healthcare
4-week rank73 / 79
Group average0.0%
Trend breadth27.8%
Trend27.8%active weekly trend signals
MD44.3%positive activity pressure
RS22.8%positive relative leadership
Four-week leaders
IndustryGB Biotechnology
4-week rank26 / 29
Group average-4.7%
Trend breadth13.8%
Trend13.8%active weekly trend signals
MD31.0%positive activity pressure
RS17.2%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape23/100
Trend, activity pressure, participation, and risk combine to a 23/100 tape read.
Indicator analysis10/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.07; No reversal markers Next-Week ExpectancyNegative 36.85%Next-week expectancy is negative with a 36.85% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors54/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment51/100Weighted news tone is neutral across 14 relevant articles.
Hemogenyx Pharmaceuticals Enters Letter of Intent with Vilnius University Hospital to Advance HG-CT-1 CAR-T Therapy for FLT3-Positive Leukemia Insiders50/100No recent insider transaction evidence is stored.
Earnings50/100No stored earnings event is currently attached to this ticker.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 6.35 GBP | 3.3% | 579.1 GBP | 595.5 GBP | -1.33 | -99.12 | 44.6K | Off |
| 31 Jul 2026 | 6.14 GBP | -15.5% | 599.6 GBP | 599.5 GBP | -1.44 | -99.15 | 67.6K | Off |
| 24 Jul 2026 | 7.27 GBP | -7.4% | 618.4 GBP | 603.3 GBP | -1.53 | -98.99 | 72.5K | Off |
| 17 Jul 2026 | 7.85 GBP | 1.3% | 638.0 GBP | 607.0 GBP | -1.60 | -98.90 | 29.2K | Off |
| 10 Jul 2026 | 7.75 GBP | 0.6% | 657.6 GBP | 611.1 GBP | -1.63 | -98.90 | 40.1K | Off |
| 3 Jul 2026 | 7.70 GBP | -1.3% | 676.5 GBP | 615.1 GBP | -1.66 | -98.94 | 13.2K | Off |
| 26 Jun 2026 | 7.80 GBP | -4.8% | 691.7 GBP | 618.8 GBP | -1.66 | -98.91 | 11.1K | Off |
| 19 Jun 2026 | 8.19 GBP | -0.8% | 711.3 GBP | 622.7 GBP | -1.50 | -98.84 | 24.0K | Off |
| 12 Jun 2026 | 8.26 GBP | 14.3% | 737.3 GBP | 625.9 GBP | -1.37 | -98.85 | 20.1K | Off |
| 5 Jun 2026 | 7.22 GBP | -99.0% | 766.2 GBP | 629.0 GBP | -1.23 | -98.99 | 32.7K | Off |
| 29 May 2026 | 698.0 GBP | 1.2% | 799.6 GBP | 633.2 GBP | -1.09 | -3.45 | 81.9K | Off |
| 22 May 2026 | 690.0 GBP | 1.5% | 805.1 GBP | 634.0 GBP | -0.94 | -3.83 | 49.9K | Off |
| 15 May 2026 | 679.5 GBP | -1.5% | 811.1 GBP | 635.0 GBP | -0.77 | -1.51 | 123.0K | Off |
| 8 May 2026 | 689.5 GBP | 1.9% | 820.7 GBP | 636.3 GBP | -0.51 | 0.89 | 88.9K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.